EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancer

Yu Yang Soon iD, Ian C Marschner, I Manjula Schou, Christopher J Sweeney, Ian D Davis, Martin R Stockler, Andrew J Martin

BJU International · 2026-01 · 137 (1) · 173-180

DOI: 10.1111/bju.70065 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, online erschienen am 05.11.2025. Verfasst von Yu Yang Soon und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Docetaxel, Phenylthiohydantoin, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Australian NHMRC Program, USA National Institutes of Health, Australian NHMRC Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To apply a trial emulation method using the ‘ENZAlutamide in first line androgen deprivation therapy for METastatic prostate cancer’ (ENZAMET) trial data to assess the effects of adding early docetaxel to enzalutamide on overall survival (OS) in metastatic hormone‐sensitive prostate cancer (mHSPC), as the benefits of adding early docetaxel to novel androgen‐receptor pathway inhibitors (ARPIs) are unclear. Patients and Methods The ENZAMET trial randomised 1125 patients with mHSPC to testosterone suppression plus enzalutamide or standard non‐steroidal antiandrogen therapy. Investigators indicated at pre‐randomisation if they planned to use early docetaxel. We emulated randomised comparisons of four treatments: (i) docetaxel plus enzalutamide, (ii) no docetaxel plus enzalutamide, (iii) docetaxel plus no enzalutamide, and (iv) no docetaxel plus no enzalutamide. Propensity score matching was applied to mitigate selection bias. OS was evaluated using Cox proportional hazards regression.

Results

Among 987 matched participants (87.7%), baseline characteristics were balanced. OS was similar with or without planned use of early docetaxel (hazard ratio [HR] 1.02, 95% confidence interval [CI] 0.92–1.12; P = 0.72), with effect modification by enzalutamide use (interaction P = 0.02). Among those assigned enzalutamide, OS was similar according to the planned use of early docetaxel or not (HR 1.18, 95% CI 0.94–1.49), regardless of disease volume (interaction P = 0.37). Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82–0.98), especially in high‐volume disease (interaction P = 0.006).

Conclusion

Early docetaxel did not appear to improve survival when added to enzalutamide, regardless of disease volume, whereas it did appear to improve survival when enzalutamide was not used, particularly in high‐volume disease. While residual confounding could not be excluded, these findings do not support the routine addition of early docetaxel to enzalutamide in mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelPhenylthiohydantoinProstatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleNitrilesBenzamidesAgedMiddle AgedAndrogen Antagonists

Stichwörter der Autor:innen

docetaxelenzalutamidemetastatic hormone‐sensitive prostate cancerpropensity score matchingtarget trial emulation

Substanzen

DocetaxelNitrilesBenzamidesenzalutamidePhenylthiohydantoinAndrogen Antagonists

Autor:innen und Institutionen

  • National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Radiation Oncology, National University Cancer Institute, Singapore, Singapore.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • South Australian Immunogenomics Cancer Institute, Adelaide, South Australia, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, New South Wales, Australia.

ORCID-Profile: Yu Yang Soon

Förderung

  • Australian NHMRC Program
  • USA National Institutes of Health
  • Australian NHMRC Investigator
  • Singapore National Medical Research Council

Zitieren

APA

Soon, Y. Y., Marschner, I. C., Schou, I. M., Sweeney, C. J., Davis, I. D., Stockler, M. R., & Martin, A. J. (2026). Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancer. BJU International, 137(1), 173-180. https://doi.org/10.1111/bju.70065

Vancouver

Soon YY, Marschner IC, Schou IM, Sweeney CJ, Davis ID, Stockler MR, et al. Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancer. BJU International. 2026;137(1):173-180. doi:10.1111/bju.70065

BibTeX
@article{Soon2026,
  author = {Soon, Yu Yang and Marschner, Ian C and Schou, I Manjula and Sweeney, Christopher J and Davis, Ian D and Stockler, Martin R and Martin, Andrew J},
  title = {Target trial emulation of early docetaxel and enzalutamide for metastatic hormone‐sensitive prostate cancer},
  journal = {BJU International},
  year = {2026},
  volume = {137},
  number = {1},
  pages = {173--180},
  doi = {10.1111/bju.70065}
}
Kostenlos starten →